Ablynx NV has appointed Andreas Menrad, former vice president of antibody therapeutics at Genzyme Corp (now Sanofi SA), as its chief scientific officer. Dr Menrad has more than 20 years of experience in the pharmaceutical and biotech industry, specifically progressing lead candidates into pre-clinical development. Prior to working for Genzyme, he held senior research positions at Schering AG. Dr Menrad received his PhD in immunology from the University of Stuttgart in 1989. He also held a post-doctoral position at the Wistar Institute Cancer Center in Philadelphia, Pennsylvania, US.
Copyright 2012 Evernow Publishing Ltd